Key facts
- It has raised $8.4M; the latest was Grant ($3.0M) in Mar 2026.
- Notable investors include European Innovation Council, European Commission, High-Tech Gründerfonds, Bundesministerium für Wirtschaft und Klimaschutz, European Social Fund — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for RAYDIAX
- ·The full record, as it builds
Funding rounds
No funding rounds for RAYDIAX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RAYDIAX
Developer of a therapeutic imaging system designed to increase the quality of minimally invasive tumor interventions. The company's system focuses on computerized tomography (CT) and uses a navigation system and a combination of 2D and 3D X-ray live imaging, enabling physicians to carry out safe, intuitive, and efficient procedures for cancer therapy.
- Sector
- Healthcare
- HQ
- Magdeburg, Germany
- Founded
- 2021
- Employees
- 21
- Website
- raydiax.com/
- Ownership
- Privately Held (backing)
RAYDIAX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RAYDIAX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RAYDIAX in its N-PORT filings yet. We sweep new filings monthly.